Final Glance: Biotechnology companies
AP - Wed Sep 10, 5:16PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were up at the close of trading:
Midday Glance: Biotechnology companies
AP - Wed Sep 10, 12:21PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 1 p.m.:
Early Glance: Biotechnology companies
AP - Wed Sep 10, 9:32AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are up at 10 a.m.:
Pluristem & United Therapeutics Progress with Phase I Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 09, 3:50PM CDT
Pluristem Therapeutics Inc. (PSTI) announced today that its licensee, United Therapeutics Corporation (UTHR), completed dosing of the first of the three cohorts of patients in a phase I study.
How Bad Is This News for Celgene Corporation?
Todd Campbell, The Motley Fool - Motley Fool - Tue Sep 09, 12:45PM CDT
When it comes to approving new drugs, the U.K. has some of the globe's toughest price negotiators. The National Institute for Health and Care Excellence, or NICE, has been anything but kind to drugmakers hoping to roll out high-priced medicine in...
Shares of CELG Up 25.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Tue Sep 09, 9:13AM CDT
SmarTrend identified an Uptrend for Celgene (NASDAQ:CELG) on May 1st, 2014 at $73.94. In approximately 4 months, Celgene has returned 25.85% as of today's recent price of $93.05.
New Center, Clinical Study Results, Collaborations, and Upcoming Event - Research Reports on Centene, Mallinckrodt, Infinity, Celgene and UnitedHealth
PR Newswire - Mon Sep 08, 7:55AM CDT
Today, Analysts Review released its research reports regarding Centene Corp. (NYSE: CNC), Mallinckrodt PLC (NYSE: MNK), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Celgene Corporation (NASDAQ: CELG) and UnitedHealth Group Inc. (NYSE: UNH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6280-100free.
IBD 50 Showing Little Distress, But Few Big Winners
at Investor's Business Daily - Fri Sep 05, 5:45PM CDT
The IBD 50 finds itself with few signs of distress, and a fair share of success stories even as the market's uptrend moderates. It's been a month since the market started climbing from its August lows, and the main indexes have slowed their ascent....
Celgene's Revlimid Impresses in Phase III NDMM Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 3:45PM CDT
Celgene's (CELG) Revlimid performed well in a late-stage study on NDMM.
Stock Market News for September 05, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 9:10AM CDT
Benchmarks reversed early gains and settled in the red zone on Thursday due to a late sell-off in energy shares
Nuvilex Aims for Market Exclusivity with Orphan Drug Status While Eyeing Larger Cancer Market for Cell-in-a-Box Technology
ACCESSWIRE - Fri Sep 05, 8:06AM CDT
New York, NY / ACCESSWIRE / September 5, 2014 / Nuvilex, Inc. (OTCQB: NVLX) has used the last two weeks to further solidify its position as a biotechnology firm, and to further its treatment for advanced pancreatic cancer, as well as, other abdominal cancers. This summer has been a starting line, of sorts, for Nuvilex to begin making the case that Cell-in-a-Box(r) should help it become a competitor in the cancer market.
Alkermes Completes Enrolment for Phase II ALKS 3831 Study - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 5:10PM CDT
Alkermes (ALKS) completed enrolling patients in a study on ALKS 3831.
Watch for Celgene to Potentially Rebound After Falling 1.06% Yesterday
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.06%, Celgene Offers Investors Better Value
Comtex SmarTrend(R) - Thu Sep 04, 3:52PM CDT
Celgene (NASDAQ:CELG) traded in a range yesterday that spanned from a low of $93.70 to a high of $95.39. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $94.26 on volume of 3.3 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.